Want to see AU:EZZ full AI Analyst Report?
EZZ Stock Chart & Stats
AU$0.52
-AU$0.02(-3.88%)
At close: 4:00 PM EDT
AU$0.52
-AU$0.02(-3.88%)
Day’s Range― - ―
52-Week RangeAU$0.36 - AU$3.38
Previous CloseN/A
Volume16.90K
Average Volume (3M)49.70K
Market Cap
AU$22.58M
Enterprise ValueAU$11.11M
Total Cash (Recent Filing)AU$13.47M
Total Debt (Recent Filing)AU$123.86K
Price to Earnings (P/E)7.8
Beta1.14
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.37%
Share Statistics
EPS (TTM)0.06
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)AU$105.10M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 70% indicate durable product pricing power and favorable unit economics for supplements. High gross margins provide buffer against input cost inflation, support marketing investment and maintain healthy operating margins over the medium term, underpinning cash generation.
Low Leverage / Strong Balance SheetA very low debt load gives the company financial flexibility to fund growth, absorb shocks, and support distributions without refinancing stress. This capital structure reduces bankruptcy risk, enables opportunistic investment or M&A, and preserves stability through economic cycles.
Robust ROE & ProfitabilityA robust return on equity reflects efficient use of shareholder capital and persistent profitability drivers. For a branded supplements business, this suggests effective pricing, distribution and cost control that can sustain returns and fund reinvestment or dividends over multiple quarters.
Bears Say
Revenue DeclineA meaningful revenue drop limits scale benefits and signals possible demand weakness or distribution disruption. Over 2-6 months this can compress margins, reduce fixed-cost absorption and weaken bargaining power with platforms or suppliers, challenging durable revenue recovery without strategic action.
Weak Cash ConversionEarnings not translating fully into operating cash suggests working capital drag or non-cash earnings items. Persistently weak cash conversion strains liquidity for capex, marketing or dividends, increases reliance on external funding and raises questions about reported profit quality over the medium term.
Declining Free Cash Flow GrowthFalling free cash flow growth reduces the company's ability to reinvest, sustain payouts or pursue strategic initiatives. Even with low leverage, declining FCF limits options, raises sensitivity to revenue volatility and may force trade-offs between growth investment and shareholder returns.
EZZ Life Science Holdings Ltd. News
EZZ FAQ
What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?
EZZ Life Science Holdings Ltd. lowest share price was AU$0.35 and its highest was AU$3.38 in the past 12 months.
What is EZZ Life Science Holdings Ltd.’s market cap?
EZZ Life Science Holdings Ltd.’s market cap is AU$22.58M.
When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?
EZZ Life Science Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 27 days.
How were EZZ Life Science Holdings Ltd.’s earnings last quarter?
EZZ Life Science Holdings Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is EZZ Life Science Holdings Ltd. overvalued?
According to Wall Street analysts EZZ Life Science Holdings Ltd.’s price is currently Overvalued.
Does EZZ Life Science Holdings Ltd. pay dividends?
EZZ Life Science Holdings Ltd. pays a Semiannually dividend of AU$0.02 which represents an annual dividend yield of 8.37%. See more information on EZZ Life Science Holdings Ltd. dividends here
What is EZZ Life Science Holdings Ltd.’s EPS estimate?
EZZ Life Science Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EZZ Life Science Holdings Ltd. have?
EZZ Life Science Holdings Ltd. has 47,043,200 shares outstanding.
What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?
EZZ Life Science Holdings Ltd. reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.326%.
Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:EZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EZZ Life Science Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:EZZ Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
8.37%
Trailing 12-Months
Asset Growth
9.62%
Trailing 12-Months
Company Description
EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories. The company's operations are divided into two distinct segments: 'Brought in Lines' and 'Company Owned products.' EZZ is actively involved in the wholesale supply of its EAORON-branded skincare portfolio, distributing it to pharmacies, major supermarkets, specialist retailers, and general grocery stores. Furthermore, the company designs, develops, manufactures, and markets a comprehensive selection of consumer health products under its own EZZ brand. This extensive offering includes vitamins, dietary supplements, sports nutrition, weight management and wellbeing solutions, traditional herbal remedies, and paediatric lines. These EZZ-branded items are sold directly to consumers via its e-commerce platforms and various retail stores, notably Tmall Global. Founded in 2015, EZZ Life Science Holdings Limited maintains its corporate headquarters in Silverwater, Australia.
Technical Analysis
Zelira Therapeutics
―
Immuron Limited
―
Anatara Lifesciences Ltd
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―